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ABSTRACT
The current version of the Human Disease Ontology
(DO) (http://www.disease-ontology.org) database ex-
pands the utility of the ontology for the examination
and comparison of genetic variation, phenotype, pro-
tein, drug and epitope data through the lens of human
disease. DO is a biomedical resource of standardized
common and rare disease concepts with stable iden-
tifiers organized by disease etiology. The content of
DO has had 192 revisions since 2012, including the
addition of 760 terms. Thirty-two percent of all terms
now include definitions. DO has expanded the num-
ber and diversity of research communities and com-
munity members by 50+ during the past two years.
These community members actively submit term re-
quests, coordinate biomedical resource disease rep-
resentation and provide expert curation guidance.
Since the DO 2012 NAR paper, there have been hun-
dreds of term requests and a steady increase in the
number of DO listserv members, twitter followers and
DO website usage. DO is moving to a multi-editor
model utilizing Prote´ge´ to curate DO in web ontol-
ogy language. This will enable closer collaboration
with the Human Phenotype Ontology, EBI’s Ontology
Working Group, Mouse Genome Informatics and the
Monarch Initiative among others, and enhance DO’s
current asserted view and multiple inferred views
through reasoning.
INTRODUCTION
Human disease data is a cornerstone of biomedical research
for identifying drug targets, connecting genetic variations
to phenotypes, understanding molecular pathways relevant
to novel treatments and coupling clinical care and biomed-
ical research (1,2). Consequently, across the multitude of
biomedical resources there is a significant need for a stan-
dardized representation of human disease to map disease
concepts across resources, to connect gene variation to phe-
notypes and drug targets and to support development of
computational tools that will enable robust data analysis
and integration (3,4). Defining a biomedical domain within
the context of an ontology creates a rigorous knowledge
backbone for the annotation of biomedical data through
defined concepts connected by specified relations (5,6). On-
tologies with their clearly-defined and well-structured de-
scriptions are vital tools for the effective application of
‘omic’ information through computational approaches.
The Human Disease Ontology (Figure 1) (7) (DO,
http://www.disease-ontology.org) is a community driven
standards-based ontology that is focused on represent-
ing common and rare disease concepts captured across
biomedical resourceswith themission of providing a disease
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Figure 1. The DO website. The query for all DO terms included in the DO Cancer slim is displayed.
interface between data resources through ongoing support
(term review and integration) of disease terminology needs.
The DO project has had a significant impact on the devel-
opment of biomedical resources, as evidenced by the body
of 95 Google Scholar citations to DO’s 2012 NAR paper
(7).
The Human DO includes only concepts of disease and
by design is meant to be a disease-focused scaffold for as-
sociating additional facts about disease. DO does not in-
clude progression (early, late, metastasis, stages) or mani-
festations (transient, acute, chronic) of disease as part of
the definition of disease. DO does not intentionally include
compound disease terms (those describing the combina-
tion of two disease terms) such as glaucoma associated with
pupillary block, rather these diseases are represented by
two distinct disease terms. DO integrates disease concepts
from ICD-9, the National Cancer Institute (NCI) The-
saurus (8), SNOMED-CT (10) and MeSH (https://www.
nlm.nih.gov/mesh/MBrowser.html) extracted from theUni-
fied Medical Language System (UMLS) (9) based on the
UMLS Concept Unique Identifiers for each disease term.
DO also includes disease terms extracted directly from On-
line Mendelian Inheritance in Man (OMIM) (11), the Ex-
perimental Factor Ontology (EFO, http://www.ebi.ac.uk/
efo/) and Orphanet (12).
THE ENHANCED HUMAN DO
In this submission, we report on major enhancements to
the DO database since 2012 including content growth, im-
proved data structure, new areas of community based cura-
tion efforts, new community partners and a switch to web
ontology language (OWL) based curation of DO. The DO
website has been maintained with periodic data updates.
Improvement of data content has been the primary focus of
the past two years. These updates further expand the utility
of DO for representing common and rare human diseases,
assessment of genomic variants among human cancers,
defining human disease within model organism databases,
unifying disparate disease representations, connecting phe-
notypes to disease and connecting Big Data knowledge be-
tween pathway, protein and drug target databases.
DO content update
We report here the expanded and more highly curated con-
tent of the DO. The DO team has committed 192 revisions
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to the HumanDO.obo file since our NAR 2012 paper. The
latest revision of DO [revision 2702, 6 October 2014] with
8803 classes (terms) [6419 non-obsolete, 2384 obsolete] rep-
resents an increase of 760 terms since DO’s previous NAR
database update (8043 terms, (7)). TheDOhas increased the
number of textual definitions from 22 to 32% of DO terms
defined (2087/6419).
During this time DO’s curatorial efforts have focused on
enriching the content of rare genetic diseases, cardiovascu-
lar diseases, neurodegenerative diseases, inheritedmetabolic
disorders, diseases related to intellectual disabilities and
cancer. The focus of these curation efforts has been driven
by requests from the research community for new terms and
by requests for review of groups of terms, review of areas of
DO or sets of disease terms being utilized within a biomed-
ical resource.
Rare genetic diseases in DO
Since the 2012 NAR paper, we have improved DO’s rep-
resentation of genetic disease and rare diseases in collabo-
ration with OMIM, Orphanet (http://www.orpha.net) and
National Organization for Rare Disorders (https://www.
rarediseases.org). These resources provide rich clinical de-
scriptions of rare disease prevalence, inheritance and epi-
demiology for the set of ∼6800 rare diseases. To date, DO
has not distinguished between rare and common disease
terms. In future revisions, DO will integrate disease preva-
lence to augment DO’s disease classification. Disease preva-
lence, defined as the proportion of a population that is af-
fected, can then be utilized to designate rare diseases in DO
and harmonize with the European (1 in 2000 affected per-
sons) and USA (fewer than 200 000 affected individuals)
definitions of rare.
DO structure updates
We report here examples of the structural improvements in
the third and fourth tier ofDO. Since the previousDONAR
report (7), the subtypes of each body system disease have
been reviewed and classified. For example, to update the
classification of cardiovascular system disease terms, Har-
rison’s Principles of Internal Medicine (13) was utilized to
more specifically categorize disease terms into four types
of cardiovascular disease: heart conduction disease, heart
disease, pericardium disease and vascular disease. All DO
terms under the cardiovascular system disease nodewere re-
viewed, their parentage was assessed and updated as needed
and additional nodes were defined as subtype categories, for
example atrioventricular block and sinoatrial node disease
were added as subtypes of heart conduction disease.
The structure of the genetic disease parent node in DO
has been restructured. Genetic diseases in DO are subtyped
into chromosomal disease or monogenic disease. There are
currently seven DO terms that do not fit into either of these
two subtypes. These diseases are subtyped directly under
genetic disease as their etiology involves causal mutations
within an unknown pattern of inheritance, multi-genic mu-
tations or multiple patterns of inheritance (e.g. Coffin-Siris
syndrome).
Automated DO to OMIM mapping pipeline
In this report, we describe the results of an automated
OMIM to DO mapping pipeline devised to identify candi-
date mappings. The pipeline was developed as part of the
DISEASES (Disease-gene associations mined from litera-
ture, http://diseases.jensenlab.org/Search) project. A dictio-
nary of DO terms and synonyms were matched to titles and
acronyms from OMIM disease pages (14). Filtering rules
were applied to achieve a one-to-one OMIM to DO map-
ping to eliminate falsematches between similarly named but
distinct OMIM titles. The filtering rules included: removal
of possessive case (e.g.Alzheimer’s), stripping punctuations,
quotes and parenthesis, removal of various prefixes and
postfixes and other ontology specific words (e.g. finding,
Ambiguous) and changingRoman numbers toArabic num-
bers. Between November 2013 and April 2014 this collab-
oration produced 658 candidate OMIM to DO mappings.
This pipeline has identified OMIM IDs (multiple pheno-
types and inheritance variants) that represent a single dis-
ease that had not previously been identified through DO’s
UMLS concept mapping or the DO team’s curation ef-
forts. For example, 16 additional OMIM IDs were identi-
fied, reviewed and integrated into DO for Alzheimer’s dis-
ease. These OMIM IDs include both ‘Phenotype descrip-
tion, molecular basis known’ (OMIM symbol #) and the
‘Phenotype description, molecular basis unknown’ (OMIM
symbol%).
Assessing disease vocabulary concept overlap
The DO continues to strive to be a resource for unify-
ing disease concepts directly through DO terms and indi-
rectly through DO’s extensive cross-mappings. Ultimately,
through collaborative development,DOhas the goal to pro-
vide a complete set of disease term concepts. Evaluation
to identify areas of DO to be augmented involves examin-
ing concept overlap. As a first step to examine the connec-
tivity of disease vocabularies via cross-references, we car-
ried out a cross-comparison analysis for seven disease vo-
cabularies: the Human DO, National Drug File Reference
Terminology (NDF-RT) disease terminology (15), NCI
Thesaurus disease terminology, Orphanet (12) Rare Dis-
ease Ontology (ORDO, http://www.orphadata.org/cgi-bin/
inc/ordo orphanet.inc.php), Comparative Toxicogenomics
Database (CTD)merged disease vocabulary (MEDIC) (16),
Kyoto Encyclopedia of Genes and Genomes (KEGG)
(17) MEDICUS, and Human Phenotype Ontology (1)
disease annotations (HPO-D). These disease vocabular-
ies contain enriched associations between disease terms
and other biomedical concepts, including drugs, genes and
phenotypes. The means of comparison is via common
cross-references. Each of these vocabularies provides cross-
references to one or more of MeSH [DO, ORDO, CTD,
NDF-RT, KEGG], OMIM [DO, ORDO, CTD, KEGG,
HPO-D], SNOMED-CT [DO, ORDO] and UMLS [DO,
ORDO, NDF-RT, KEGG, NCI]. Furthermore, HPO-D
contains ORDO cross-references, which in turn can be ex-
panded by means of any ORDO cross links to MeSH,
OMIM, SNOMED-CT and UMLS to create an indirect
set of cross-references from HPO-D to MeSH, OMIM,
SNOMED-CT and UMLS.
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UMLS includes a meta-thesaurus that combines health
and biomedical vocabularies using grouping and sematic in-
tegration of synonymous relationships. MeSH, OMIM and
SNOMED-CT are among the UMLS source vocabularies;
therefore, cross-references to disease concepts fromMeSH,
OMIM or SNOMED-CT were further (indirectly) mapped
to a UMLS disease concept (when such a cross mapping
exists within UMLS).
All MeSH, OMIM, SNOMED-CT and UMLS cross-
reference links (directly provided by a disease vocabulary or
indirectly derived as described above) were used in the com-
parison analysis. To justify our cross-mapping approach,
we have also carried out overlap analysis either without di-
rect links through MeSH, OMIM and SNOMED-CT, or
without indirect links through UMLS (see Supplementary
Tables S1 and S2). The overlap analysis of cross-references
between disease vocabularies changed markedly for practi-
cal reasons. For example, using only UMLS for the overlap
analysis excluded a number of disease-related OMIM cross-
references that did not have a corresponding UMLS con-
cept. Similarly, excluding any indirect UMLS links prevents
NCI from having significant overlap with other disease vo-
cabularies, as NCI does not provide any MeSH, OMIM or
SNOMED-CT cross-references.
The sizes of the disease vocabularies cross-comparedwith
DO are provided in Table 1 (see also Supplementary Ta-
ble S3). TheNDF-RT ontological framework organizes dis-
ease concepts into a hierarchical structure derived from
the MeSH vocabulary, and it explicitly asserts different re-
lations between drugs and diseases. NCI Thesaurus inte-
grates different kinds of concept schemes and their inter-
relationships in a unified conceptual framework. NCI dis-
ease terms belong to six semantic types, including disease
or syndrome, neoplastic process, pathologic function, men-
tal or behavioral dysfunction, sign or symptom and ab-
normality. ORDO integrates Orphanet multi-hierarchical
classifications of rare diseases with semantic interoper-
ability. KEGG MEDICUS contains integrated informa-
tion for drugs, diseases and other health-related concepts.
CTD MEDIC has been employed to hierarchically anno-
tate disease-associated toxicogenomic relationships and is
derived from MeSH and OMIM. MEDIC disease terms
were downloaded, and all of the primary/alternativeMeSH
and OMIM identifiers including the MEDIC Slim identi-
fiers were used in the cross-comparison analysis. HPO-D
provides genetic disease annotations for human phenotypic
abnormalities using disease concepts in OMIM, Orphanet
and DECIPHER databases.
Cross-comparison results and conclusions
The count of unique cross-references provided by each dis-
ease vocabulary is summarized in Table 2. UMLS links re-
ported in this table are provided in both ‘indirect’ (i.e. de-
rived via UMLS from MeSH, OMIM and SNOMED-CT
links) and ‘direct’ (i.e. provided directly by the vocabulary)
form along with the unique count of the union of these two
links being ‘combined’, showing there can be substantial
uniqueUMLS cross-references provided using the ‘indirect’
linking method but also strong overlap.
It is worth noting that DO provides the largest num-
ber of unique cross-references (35 895), which contributes
∼64% of the total number of unique cross-references (Ta-
ble 2). This emphasizes DO’s role as a resource rich in
cross-references and usefulness as a disease-centric scaffold
for data. On average, each DO term has more than four
cross-references (35 895/8757). The large number of cross-
references indicates the role of the DO in interoperability in
the DO domain.
Mapping methodology
If any two disease terms from different disease vocabularies
shared one or more cross-references, identity was assumed
and they were treated as synonymous terms. Each vocabu-
lary has its own emphases on particular disease categories.
For instance, ORDO and HPO-D are primarily comprised
genetic diseases, and NCI Thesaurus has specific focus on
cancers. Not surprisingly, ORDO and HPO-D have a high
degree of overlap with each other, and other disease vocabu-
laries may have a low degree of overlap with them (Table 3).
It is noteworthy that most disease vocabularies have very
low overlap with NCI Thesaurus except DO. DO has more
general coverage of disease categories, but still a relatively
low degree of overlap with the rare diseases represented in
ORDO and HPO-D, and has moderate overlap with CTD,
NDF-RT and KEGG diseases and has high overlap with
NCI cancer diseases (Table 3).
The percent overlap between the seven different disease
vocabularies is presented in Table 4. There are a number of
observations apparent. KEGG has the fewest disease terms
and, therefore, a limited ability to cover the disease concepts
used by other terminologies; however, it does so rather ef-
fectively, covering 56% of CTD and 50% of ORDO. HPO-
D extensively uses ORDO to annotate their disease-related
terms, so it may not be a surprise that it covers 87% of the
ORDO disease terms. For the same reason, it is not very
surprising that HPO-D and ORDO both cover about the
same amount of the KEGG disease concepts. NCI, with
its emphasis on cancer, has limited overlap (at most 38%)
with the other disease terminology concepts. NDF-RT’s fo-
cus on druggable diseases appears to limit its coverage of
known diseases without treatments, but it still covers more
than half of CTD and KEGG disease concepts. Lastly, it
is rather interesting to compare the cross-coverage of CTD
and DO. Clearly, CTD covers druggable targets better than
DO (as manifest by 99% coverage of NDF-RT) but has lim-
ited coverage of cancer disease concepts (as indicated by a
24% overlap with NCI).
Alternatively, DO has good coverage of cancer concepts
(as indicated by 87% overlap with NCI) but has only mod-
erate coverage of druggable/treatable diseases (as indicated
by a 61% overlap with NDF-RT). This indicates areas of
strength and improvement for DO to cover additional dis-
ease concepts (e.g. by identifying missing NDF-RT disease
concepts).
Updates to the DO website
The current version of the DO website (7) (version 1.0) pro-
vides a comprehensive resource to perform full-text search-
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Table 1. The seven disease vocabularies being cross-compared.
Vocabulary Data source Size Access date
DO Subclasses of root disease concept () 8,757 26 March 2014
NDF-RT Subclasses of root disease concept (N0000000004) 4,700 26 March 2014
NCI Subclasses of root disease concept (C2991) 4,252 11 August 2014
ORDO Subclasses of root disease concept (Orphanet C001) 4,799 27 March 2014
KEGG All of KEGGMEDICUS disease concepts 1,359 30 March 2014
CTD All of MEDIC disease concepts 11,898 08 April 2014
HPO-D All of hereditary syndromes with phenotypic information 7,520 07 August 2014
Table 2. The number of unique cross-references in each disease vocabulary.
MeSH OMIM SNOMED-CT UMLS direct
UMLS
indirecta
UMLS
combined Total
DO 2,908 1,864 13,276 12,170 8,354 13,004 35,895
ORDO 1,705 5,201 1,943 7,997 2,285 8,071 16,920
CTD 11,332 3,977 0 0 6,650 6,650 21,959
NDF-RT 4,661 0 0 4,699 7,922 8,245 12,906
KEGG 1,295 2,690 0 0 4,482 4,482 8,467
HPO-D 0 6,528 0 0 8,000 8,000 14,528
NCI 0 0 0 3,910 0 3,910 3,910
Totalb 11,467 7,389 14,362 13,486 23,251 23,251 56,469
aInferred UMLS cross-references were obtained by UMLS mapping to MeSH, OMIM and SNOMED-CT concepts.
bTotal number of unique cross-references.
Table 3. The overlap between disease vocabularies.
DO ORDO CTD NDF-RT KEGG HPO-D NCI
DO 8,757a 1,492 3,432 3,200 1,102 1,278 2,092
ORDO 1,952 4,799a 3,503 1,465 2,383 4,170 993
CTD 6,413 6,418 11,898a 6,701 6,607 2,883 2,345
NDF-RT 2,878 1,091 4,660 4,700a 775 876 1,686
KEGG 854 1,105 1,303 718 1,359a 1,102 522
HPO-D 2,291 5,426 3,818 1,169 3,102 7,520a 818
NCI 3,692 888 1,004 1,865 625 694 4,252a
The number of identical terms between any two disease vocabularies indicates the degree of overlap between them. The off-diagonal numbers in the overlap
matrix can be interpreted as the number of terms from the row disease resource covered by the column disease resource. For example, DO has common
cross-references with 1492 of the 4799 ORDO terms, while ORDO has common cross-references with 1952 of the 8757 DO terms. The diagonal numbers
in the overlap matrix indicate the total number of terms in each disease resource.
aThe total number of disease terms in each disease vocabulary.
Table 4. The percentage overlap between disease vocabularies.
DO
DO
–
41%
54%
61%
63%
30%
87%
56%
17%
–
54%
23%
81%
72%
21%
45%
39%
73%
99%
96%
51%
24%
64%
–
37%
31%
56%
53%
16%
44%
40%
–
13%
50%
56%
16%
41%
15%
32%
–
87%
24%
19%
81%
16%
40%
–
21%
20%
36%
38%
11%
25%
–
15% 24%
ORDO
ORDO
CTD
CTD
NDF-RT
NDF-RT
KEGG
KEGG
HPO-D
HPO-D
NCI
Color Code 0–25% 25–50% 50–75% 75–100%
NCI
Averagea
Identical to Table 3 except where the overlaps are provided in percent-
age form. The diagonal values are omitted for clarity. The percentages are
color-coded using four range categories: white for low overlap, light gray
for moderately low overlap, medium gray for moderately high overlap and
dark gray for high overlap.
aAverage value for each column calculated by adding the numbers in each
columnand dividing by six.
ing on the DO as well as exploring and visualizing relation-
ships between terms. TheDO database website has been up-
dated periodically since 2012 to include major data releases.
TheDOwebsite provides links toDO related resources (DO
tracker, downloading the HumanDO.obo file and DO tu-
torial). The Resources Tab has been augmented with links
to disease––gene resources (FunDO (18), BioconductorGe-
neAnswers (19)) and downloads of the DO Neo4j database
on GitHub. The DO API allows for querying of terms for
a specific DOID through a REST-style URL. For example,
the URL for DOID:11725 is http://www.disease-ontology.
org/term/DOID:11725/.
DO site usage and mappings statistics
Following DO’s 2012 NAR paper, the number of sessions
and users (Google Analytics) on the DO website has risen
dramatically, with the number of returning visitors rising
from 18 to 58% betweenDecember 2011 and June 2014 (Ta-
ble 5).
The extent of DO’s ontology mappings between BioPor-
tal ontologies demonstrates the extended of usage of DO
as a disease domain ontology. As of 15 September 2014,
BioPortal has mapped DO classes to classes within 128
other BioPortal ontologies (http://bioportal.bioontology.
org/ontologies/DOID/?p=mappings).
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Table 5. Google analytics reporting for the DO website.
Time frame Sessions Users Returning visitors New visitors
8/31/2013–9/1/2014 11,517 (total) 6,206 47% 53%
December 2011 539 (per month) 446 18% 82%
June 2014 1,385 (per month) 681 58% 42%
The increased number of visits (sessions), number of users and percent of returning visitors to the DO website over the past year and monthly averages
between December 2011 and June 2014.
Table 6. The number of DO terms mapped to biomedical resources.
Biomedical resource Data types DO disease mappings
Reactome Disease to pathway 770+
Neurocarta Disease to gene associations 1,920
FlyBase Human disease models - Drosophila alleles 2,289
PRO Protein-disease 50
EFO EFO-DO 137
NeuroDevNet Intellectual disabilities 71
Inherited metabolic disorders 80
DO AVAILABILITY
The DO Neo4j database, HumanDO.obo and
HumanDO.owl files are available under the Cre-
ative Commons Attribution 3.0 Unported License
(http://creativecommons.org/licenses/by/3.0/) which
allows for the copying, redistribution and adap-
tion of the ontology for any purpose. The DO files
are available in both OBO and OWL format from
DO’s SourceForge site (http://sourceforge.net/p/
diseaseontology/code/HEAD/tree/trunk) and can be
found at http://purl.obolibrary.org/obo/doid.obo and http:
//purl.obolibrary.org/obo/doid.owl. DO’s Neo4j database
is on GitHub (http://github.com/IGS/disease-ontology).
DO’s OBO and OWL files are also available from the
OBO Foundry (http://www.obofoundry.org/cgi-bin/detail.
cgi?id=disease ontology) and GitHub (http://github.com/
obophenotype/human-disease-ontology/HumanDO.owl).
Community feedback and data submissions
The DO team receives community feedback on a contin-
ual basis through individual new term requests, requests for
definition, synonym or term updates and requests for ex-
planations of the DO curatorial process and curation deci-
sions. Requests are received through multiple methods in-
cluding DO’s SVN term tracker (http://sourceforge.net/p/
diseaseontology/feature-requests/), DO’s Contact Us (http:
//www.disease-ontology.org/contact/), through DO’s web-
site feature ‘Add an item to the term tracker’ found at the
bottom of each metadata page for each DO term, and di-
rect emails to theDOPIs. TheDO listserv (diseaseontology-
discussion) has received over 200 submissions sinceNovem-
ber 2011. The DO team has fielded 106 distinct postings
through theDOwebsite (DOdisease-ontology.org requests)
and 59 feature requests through the DO SVN site. Each re-
view request involves examination of the current disease in-
formation in DO and examination of current literature and
online expert resources (e.g. GeneReviews (20), Orphanet,
OMIM, NIH Institutes and MayoClinic) to identify the
most appropriate classification for each disease term. The
DO team provides prompt replies to each user request at
the conclusion of the curation.
Examples of the most often types of requests include: re-
fining DO textual definitions, creating new DO classes (e.g.
25 new DO terms for the fission yeast database), adding
DO terms for a set of diseases (e.g. dystonia diseases), term
name fixes, term status (obsolete), adding comments to ob-
solete DO records, adding synonyms from publications to a
DO term, removing term redundancy among the synonyms,
adding apostrophe free synonyms to disease terms, identify-
ing typos in term names or definitions, adding OMIM IDs
to specific DOIDs, updating term parentage or adding rela-
tions to definitions to further clarify etiology.
Large-scale community data submissions
We report here DO’s collaborative efforts with biomedical
resources over the past two years. DO provides individual
curation efforts to coordinate, map and integrate the dis-
ease terms used by each biomedical resource. DO works
directly with community members providing disease cura-
tion to support disease representation among the Model
Organism Databases (FlyBase (Susan Tweedie), Worm-
Base (Ranjana Kishore), PomBase (Antonia Lock), within
pathway (Reactome: Peter D’Eustachio) and epitope (Im-
mune Epitope Database (IEDB), Bjorn Peters IEDB Dis-
ease Finder, http://www.iedb.org/home.php) databases and
to foster the development of gene––variant––phenotype
resources (e.g. Gene Wiki (21), OMIM API) and can-
cer variant projects (e.g. The Jackson Laboratory for Ge-
nomic Medicine (http://www.jax.org/ct/), HIVE (22)). The
Biomuta–HIVE project is ongoing. The DO team is collab-
oratively building aDO Cancer Slim (366 termsmapped to
70 term DO Cancer Slim) derived from cancer terms from:
COSMIC, UniProt, TCGA, IntOGen, ICGC and publica-
tions. The DOCancer Slim collaborators include the HIVE
team, COSMIC, Novartis and EDRN. The Project Lead-
ership Team includes Raja Mazumder, Tsung-JungWu and
Krista Smith (George Washington University).
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Biomedical resources incorporating DO
DO terms and IDs are being used to develop and build algo-
rithms, computational tools and biomedical resources. DO
has been incorporated into a growing number of biomed-
ical resources including the EBI Array Express (23), the
Neuroscience Information Network (NIFSTD) (24), Neu-
rocarta (25), NeuroDevNet (26), Infectious Disease On-
tology (http://infectiousdiseaseontology.org), the MIxS ge-
nomic metadata standard (27) and the NIH Library of In-
tegrated Network-based Cellular Signatures program (28).
DOhas provided diseasemappings in the past year across
a number of biomedical resources (Table 6). Additionally,
theDO teamhas ongoing interactions withMouseGenome
Informatics (MGI) (mapping OMIM to DO), dictyBase,
EMBl EBI Samples, Phenotypes and Ontology team, the
HPO, OMIM (omim.org), Orphanet, PubChem, the Sifem
Inner Ear disease project (http://www.sifem-project.eu),
cognitive atlas (http://www.cognitiveatlas.org): a knowledge
base formental function, the ProteinOntology (PRO) (http:
//pir.georgetown.edu/pro/pro.shtml), theMonarchDiseases
and Phenotype project (http://monarchinitiative.org) and
Gene Wiki.
DO has become a disease knowledge resource for the
further exploration of biomedical data including measur-
ing disease similarity based on functional associations be-
tween genes (29), as a disease data source for the building
of biomedical databases, e.g. cdGO: an ontology database
for protein domains (http://supfam.org/SUPERFAMILY/
dcGO) (30) and defining disease-gene relationships, e.g.
DGA: Disease and Gene annotations resource (31).
FUTURE DIRECTIONS
The DO team recognized the imperative need to provide
definitions for all DO terms. Integration of textual defini-
tions for all DO terms is a major curatorial effort of the DO
team in the next year. DO is moving to a multi-editor cura-
tion model in the fall of 2014 in order to improve DO’s in-
teroperability, to enable integration of cross products within
DO and to develop inferred DO hierarchies (genetic, clini-
cal) in addition to DO’s asserted etiology-based hierarchy.
This work will involve: moving curation effort to Prote´ge´
(coordinated by Chris Mungall) to use OWL and reason-
ing; creating cross product terms for better interoperability
with the OBO Foundry ontologies; and engaging commu-
nity partners (EBI, MGI, HPO and Orphanet) and cardio-
vascular and metabolic disease clinicians to join DO as ed-
itors and data reviewers. An initial list of the types of data
that will be added to DO, along with their associated re-
lations, has been proposed and will undergo additional re-
view within the DO group and among community ontol-
ogy partners including Barry Smith. The data types, source
ontologies and relations to be added to DO include: phe-
notypes (HPO/PATO: has phenotype), symptoms (SYMP:
has symptom), age of onset (HPO), anatomical location
(UBERON: located in), GO annotations (Gene Ontology:
disregulated in), cells/tissues of origin (Cell ontology: de-
rives from or has material basis in) and types of inheri-
tance (has physical basis in). For example, the DO term in-
halation anthrax is currently defined as ‘is a anthrax dis-
ease’. The addition of UBERON (32) cross products will
utilize the located in relation to connect the DO term to
the UBERON terms lung (UBERON:0002048) and lymph
node (UBERON:0000029).
DO website: future directions
Additional development of the DO website is planned over
the next year. Version 2.0 of the DO website will include
bulk querying and API development, saving of queries and
result datasets and better direct-link support to DO terms.
An enhanced DO API will allow users to perform any ac-
tion that they can do interactively on the website via the
API. This will include searching using all fields provided,
pulling down static images of visualized term relationships
and pulling down single or many sets of termmetadata. Ex-
pansion of the API will provide another robust resource to
allow tech-savvy users to scrape or pull down large amounts
of metadata for use in their own websites, web applications
or bulk analysis.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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